The Food and Drug Administration granted accelerated approval to pembrolizumab (KEYTRUDA, Merck) for patients with metastatic small cell lung cancer (SCLC) with disease progression on or after platinum-based chemotherapy and at least one other prior line of therapy.
Efficacy was investigated in 83 patients with SCLC who had disease progression on or after two or more prior lines of therapy enrolled in one of two multicentre, multi-cohort, non-randomised, open label trials: KEYNOTE-158 (NCT02628067) Cohort G or KEYNOTE-028 (NCT02054806) Cohort C1.
Patients received either pembrolizumab 200 mg intravenously every 3 weeks (n=64) or 10 mg/kg intravenously every 2 weeks (n=19).
Treatment continued until documented disease progression, unacceptable toxicity, or a maximum of 24 months.
The main efficacy outcome measures were overall response rate (ORR) and duration of response (modified RECIST v1.1) assessed by blinded independent central review.
The ORR was 19% (95% CI: 11, 29); the complete response rate was 2%.
Responses were durable for 6 months or longer in 94%, 12 months or longer in 63%, and 18 months or longer in 56% of the 16 responding patients.
Adverse reactions in patients who received single-agent pembrolizumab for previously treated SCLC were similar to those occurring in patients with other solid tumours who received pembrolizumab.
Common adverse reactions reported in at least 20% of patients include fatigue, decreased appetite, cough, nausea and constipation.
Pembrolizumab was discontinued for adverse reactions in 9% of patients and 25% had at least one dose withheld for adverse reactions.
Serious adverse reactions occurred in 31%.
The most frequent (≥2%) serious adverse reactions were pneumonia and pleural effusion.
The recommended pembrolizumab dose for SCLC is 200 mg administered as an intravenous infusion over 30 minutes every 3 weeks until disease progression, unacceptable toxicity, or up to 24 months in patients without disease progression.
Source: The Food and Drug Administration